Clinician's Digest

Clinician's Digest

By Garry Cooper

May/June 2008

For the second time in six years, a metanalysis led by psychologist Irving Kirsch asserts that antidepressants are no more effective than placebos (see November/December 2002 Networker). Like his earlier analysis, Kirsch analyzes both published clinical trials and the raw data that pharmaceutical companies are required to submit to the Food and Drug Administration. This time, Kirsch asks whether the same antidepressants he studied earlier—Prozac, Effexor, Serzone, and Paxil—work better than placebo on severe depression. The answer, he says, is still no.

Kirsch insists that using the raw data enables him to avoid the well-known bias toward positive results inherent in published studies of antidepressants. A study in the January 17 New England Journal of Medicine, for example, reports that 94 percent of the published trials were positive, whereas only about 50 percent the unpublished studies were. Raw data, unlike published studies, aren't methodologically tweaked to insure positive results.

Like Kirsch's earlier study, the new one, in the February online journal Public Library of Science Medicine, has generated considerable controversy. Much of the criticism focuses on his decisions about what constitutes clinical effectiveness, which his detractors say were arbitrary and ignored the considerable number of individuals who show marked improvement. Using the same data as Kirsch, psychiatrist Eric Turner and psychologist Robert…

Already have an account linked to your magazine subscription? Log in now to continue reading this article.

(Need help? Click here or contact us to ask a question.)

Not currently a subscriber? Subscribe Today to read the rest of this article!

Previous: Case Studies
Next: Bookmarks

Read 11469 times
Comments - (existing users please login first)
Your email address will not be published. Required fields are marked *